Pharmacological strategies to manage oxidative stress in Huntington’s disease: from preclinical models to clinical trials
Frontiers in Pharmacology · 30.10.2026 · 17
DOI: 10.3389/fphar.2026.1984341 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.10.2026. Verfasst von Sylwester Dumała und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland. Die Arbeit nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki.
Abstract (Originalsprache)
Huntington disease (HD) is a progressive neurodegenerative disorder for which effective disease-modifying treatments remain limited. Growing evidence indicates that oxidative stress, mitochondrial dysfunction, and impaired cellular antioxidant responses are important contributors to HD pathogenesis and may interact with mechanisms that drive disease progression, including somatic CAG repeat expansion. This narrative review examines therapeutic strategies aimed at restoring redox balance in HD, with particular emphasis on approaches targeting mitochondrial function, antioxidant defense, glutathione metabolism, lipid oxidation, and metal homeostasis. Although a broad range of compounds has shown beneficial effects in experimental models, translation into clinical benefit has so far been limited. This gap may reflect insufficient target engagement, inadequate brain exposure, intervention at advanced disease stages, and the difficulty of capturing biologically meaningful effects using conventional clinical endpoints. Future therapeutic development may therefore benefit from earlier intervention, biomarker-guided patient stratification, combination strategies integrating redox modulation with huntingtin-lowering approaches, and the repurposing of clinically established drugs targeting mitochondrial and redox pathways.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland.
- Department of Neurology, St. Adalbert Hospital, Gdansk, Poland.
- Department of Neurology, Neurodegenerative Disorders and Neuroimmunology, Faculty of Health Sciences, Medical University of Gdansk, Gdansk, Poland.
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Förderung
- Narodowe Centrum Nauki
Zitieren
APA
Dumała, S., Jedrzejewska, A., Kwaśniak-Butowska, M., De Sousa, P. A., & Tomczyk, M. (2026). Pharmacological strategies to manage oxidative stress in Huntington’s disease: from preclinical models to clinical trials. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1984341
Vancouver
Dumała S, Jedrzejewska A, Kwaśniak-Butowska M, De Sousa PA, Tomczyk M. Pharmacological strategies to manage oxidative stress in Huntington’s disease: from preclinical models to clinical trials. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1984341
BibTeX
@article{Dumaa2026,
author = {Dumała, Sylwester and Jedrzejewska, Agata and Kwaśniak-Butowska, Magdalena and De Sousa, Paul A and Tomczyk, Marta},
title = {Pharmacological strategies to manage oxidative stress in Huntington’s disease: from preclinical models to clinical trials},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1984341}
}
EUVIMED